cis-Diamminedichloroplatinum(2)による泌尿性器悪性腫瘍の治療

Abstract

cis-Diamminedichloroplatinum (cisplatin) treatment for urogenital malignancies was presented as phase I and phase II studies. Five cases, including 3 cases of bladder tumor, one of ureteral tumor and one of Wilms' tumor, were subjected to phase I study. It was demonstrated that cisplatin was safely given in a dosage of 10 mg for 5 consecutive days. Adverse effects were mainly gastrointestinal, such as nausea, vomiting, and anorexia. Nine cases, including 8 cases of testicular tumor and one of renal cell carcinoma, were subjected to phase II study. Koyama-Saito's and Karnofsky's criteria were adopted for the evaluation of clinical effectiveness. Cisplatin was given in a total dosage of 160mg-790mg. Overall response rate was 22.2%. In terms of testicular tumor it was 25%. Among the cases with testicular tumor, one showed complete remission with complete disappearance of pulmonary metastases. Toxicities were the same as seen in phase I study. Nephrotoxicity, difficulty of hearing, hematopoietic toxicity and hepatotoxicity were not major problems in this series of patients. From these studies it was assumed that this agent was effective for the treatment of urogenital malignancies, especially testicular tumor.